CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy
S McNeely1, R Beckmann1, A K Bence Lin1
1Eli Lilly and Company, Indianapolis, IN, United States.
Abstract:
CHEK1 encodes the serine/threonine kinase CHK1, a central component of the DNA damage response. CHK1 regulates cell cycle checkpoints following genotoxic stress to prevent the entry of cells with damaged DNA into mitosis and coordinates various aspects of DNA repair. Accordingly, CHK1 has become a target of considerable interest in oncology. CHK1 inhibitors potentiate the efficacy of DNA-damaging chemotherapeutics by abrogating CHK1-mediated cell cycle arrest and preventing repair of damaged DNA. In addition, CHK1 inhibitors interfere with the biological role of CHK1 as a principal regulator of the cell cycle that controls the initiation of DNA replication, stabilizes replication forks, and coordinates mitosis. Since these functions of CHK1 facilitate progression through an unperturbed cell cycle, CHK1 inhibitors are being developed not only as chemopotentiators, but also as single-agent therapies. This review is intended to provide information on the current progress of CHK1 inhibitors in pre-clinical and clinical development and will focus on mechanisms of single-agent activity and potential strategies for patient tailoring and combinations with non-genotoxic agents.
Insights
Checkpoint kinase 1 (CHEK1) inhibitors are promising cancer therapies. They enhance chemotherapy and may work as single agents by disrupting cell cycle regulation and DNA repair in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Checkpoint kinase 1 (CHEK1) is crucial for the DNA damage response.
- CHEK1 regulates cell cycle checkpoints and DNA repair following genotoxic stress.
Purpose of the Study:
- To review the progress of CHEK1 inhibitors in preclinical and clinical development.
- To explore mechanisms of single-agent activity and combination strategies for CHEK1 inhibitors.
Main Methods:
- Literature review of preclinical and clinical studies on CHEK1 inhibitors.
- Analysis of CHEK1's role in cell cycle regulation, DNA replication, and mitosis.
Main Results:
- CHEK1 inhibitors potentiate DNA-damaging chemotherapeutics by blocking cell cycle arrest and DNA repair.
- CHEK1 inhibitors also function as single-agent therapies by interfering with normal cell cycle progression.
Conclusions:
- CHEK1 inhibitors show potential as both chemopotentiators and single-agent therapies in oncology.
- Further research is needed to optimize patient selection and combination strategies for CHEK1 inhibitors.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...